Scott North

19.3k total citations · 2 hit papers
193 papers, 7.6k citations indexed

About

Scott North is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Scott North has authored 193 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Pulmonary and Respiratory Medicine, 74 papers in Oncology and 50 papers in Cancer Research. Recurrent topics in Scott North's work include Prostate Cancer Treatment and Research (63 papers), Renal cell carcinoma treatment (56 papers) and Bladder and Urothelial Cancer Treatments (32 papers). Scott North is often cited by papers focused on Prostate Cancer Treatment and Research (63 papers), Renal cell carcinoma treatment (56 papers) and Bladder and Urothelial Cancer Treatments (32 papers). Scott North collaborates with scholars based in Canada, United States and Australia. Scott North's co-authors include Kim N., Christian Kollmannsberger, Toni K. Choueiri, Peter Venner, Brian I. Rini, Jennifer J. Knox, Fred Saad, Daniel Y.C. Heng, Wanling Xie and Bernhard J. Eigl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Scott North

185 papers receiving 7.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 1.5k citations Daniel Y.C. Heng, Bernhard J. Eigl et al. Journal of Clinical Oncology profile →
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

2012 1.0k citations Karim Fizazi, Howard I. Scher et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Scott North	5.5k	2.8k	2.6k	2.2k	1.2k	193	7.6k
Daniel J. George	4.7k 0.9×	2.9k 1.0×	3.3k 1.3×	1.9k 0.9×	913 0.7×	255	8.0k
Gwénaëlle Gravis	6.3k 1.1×	3.4k 1.2×	2.2k 0.9×	2.1k 1.0×	1.8k 1.4×	368	9.2k
Wanling Xie	5.5k 1.0×	2.9k 1.0×	3.2k 1.2×	2.4k 1.1×	491 0.4×	181	7.8k
Ugo De Giorgi	4.7k 0.8×	3.8k 1.4×	2.3k 0.9×	2.4k 1.1×	1.1k 0.9×	489	9.0k
Peter Venner	4.8k 0.9×	3.3k 1.2×	1.9k 0.8×	1.5k 0.7×	711 0.6×	116	8.4k
Neeraj Agarwal	5.9k 1.1×	4.2k 1.5×	2.6k 1.0×	2.5k 1.1×	1.3k 1.0×	437	9.4k
Aude Fléchon	4.9k 0.9×	2.6k 0.9×	1.8k 0.7×	1.5k 0.7×	1.6k 1.3×	273	7.7k
Manuela Schmidinger	5.4k 1.0×	3.0k 1.1×	3.9k 1.5×	2.3k 1.0×	517 0.4×	180	8.5k
Tomasz Demkow	4.3k 0.8×	2.2k 0.8×	3.6k 1.4×	2.3k 1.0×	414 0.3×	77	6.6k
Bhumsuk Keam	4.0k 0.7×	6.1k 2.2×	2.1k 0.8×	1.6k 0.7×	667 0.5×	373	9.9k

Countries citing papers authored by Scott North

Since Specialization

Citations

This map shows the geographic impact of Scott North's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott North with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott North more than expected).

Fields of papers citing papers by Scott North

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott North. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott North. The network helps show where Scott North may publish in the future.

Co-authorship network of co-authors of Scott North

This figure shows the co-authorship network connecting the top 25 collaborators of Scott North. A scholar is included among the top collaborators of Scott North based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott North. Scott North is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

North, Scott, et al.. (2025). Multicenter examination of contemporary penile prosthesis surgery infection prophylaxis practices. The Journal of Sexual Medicine. 22(8). 1531–1533.

Agarwal, Neeraj, Arun Azad, Joan Carles, et al.. (2024). CONTACT-02: Phase 3 study of cabozantinib (C) plus atezolizumab (A) vs second novel hormonal therapy (NHT) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 42(4_suppl). 18–18. 20 indexed citations

Davis, Ian D., Robert Zielinski, Alastair Thomson, et al.. (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. Journal of Clinical Oncology. 42(16_suppl). 5079–5079. 3 indexed citations

Basappa, Naveen S., et al.. (2024). Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer. Current Oncology. 31(9). 5080–5087. 1 indexed citations

Agarwal, Neeraj, Arun Azad, Stéphane Oudard, et al.. (2024). LBA67 Cabozantinib (C) plus atezolizumab (A) versus 2nd novel hormonal therapy (NHT) in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC): Final overall survival (OS) results of the phase III, randomized, CONTACT-02 study. Annals of Oncology. 35. S1256–S1257. 4 indexed citations

Blais, Normand, Nimira Alimohamed, Lori Wood, et al.. (2024). 2024 CUA-GUMOC Expert Report: Management of unresectable locally advanced and metastatic urothelial carcinoma. Canadian Urological Association Journal. 18(12). 379–90. 1 indexed citations

Yip, Steven, Michael Kolinsky, Kosuke Takemura, et al.. (2023). 1799P Real-world (RW) treatment (tx) patterns of metastatic prostate cancer (mPCa) with enhanced access to homologous recombination repair (HRR) genomic testing and poly ADP ribose polymerase inhibitor (PARPi). Annals of Oncology. 34. S972–S972. 1 indexed citations

Horvath, Lisa G., Ian D. Davis, Andrew Martin, et al.. (2023). 1792P Effects of enzalutamide on overall survival +/- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Annals of Oncology. 34. S968–S969. 2 indexed citations

Navani, Vishal, T.B. Powles, Luís Meza, et al.. (2023). 1893P Immune-related adverse events from contemporary first-line combination therapies in metastatic renal cell carcinoma: Results from the IMDC. Annals of Oncology. 34. S1018–S1019. 1 indexed citations

10.

Graham, Jeffrey, J. Connor Wells, Shaan Dudani, et al.. (2022). Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer. 171. 124–132. 20 indexed citations

11.

Jiang, Di, Scott North, Christina Canil, et al.. (2020). Current Management of Localized Muscle-Invasive Bladder Cancer: A Consensus Guideline from the Genitourinary Medical Oncologists of Canada. Bladder Cancer. 6(3). 363–392. 2 indexed citations

12.

Li, Haocheng, Scott North, Raya Leibowitz‐Amit, et al.. (2018). The Prognostic Role of the Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer: A Retrospective, Multi-Institutional Study. Bladder Cancer. 4(2). 185–194. 18 indexed citations

13.

Vandekerkhove, Gillian, Tilman Todenhöfer, Matti Annala, et al.. (2017). Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research. 23(21). 6487–6497. 122 indexed citations

14.

N., Kim, Jennifer L. Spratlin, Christian Kollmannsberger, et al.. (2015). Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer. The Journal of Clinical Pharmacology. 55(12). 1406–1414. 82 indexed citations

15.

Vicente, Carlos Disdier, et al.. (2015). Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt). Value in Health. 18(7). A474–A474. 1 indexed citations

16.

Saad, Fred, Sébastien J. Hotte, Charles Catton, et al.. (2013). CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. Canadian Urological Association Journal. 7(7-8). 231–231. 15 indexed citations

17.

Heng, D.Y.C., Toni K. Choueiri, Brian I. Rini, et al.. (2013). Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Annals of Oncology. 25(1). 149–154. 113 indexed citations

18.

Noonan, Krista, Scott North, Rhonda L. Bitting, et al.. (2013). Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Annals of Oncology. 24(7). 1802–1807. 256 indexed citations

19.

Sternberg, Cora N., A. Molina, Scott North, et al.. (2012). Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Annals of Oncology. 24(4). 1017–1025. 70 indexed citations

20.

Heng, D.Y.C., Mary J. MacKenzie, Ulka N. Vaishampayan, et al.. (2011). Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Annals of Oncology. 23(6). 1549–1555. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact